News

News

Press Releases | Publications | In the News

Press Releases

Press releases

May 13, 2024
Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer
May 16, 2023
Ensoma Closes Series B Extension, Bringing Total Round to $135 Million
February 9, 2023
Ensoma Announces Closing of Twelve Bio Acquisition
January 5, 2023
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
October 28, 2021
Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies
October 11, 2021
Ensoma Appoints Cell and Gene Therapy Pioneer Emile Nuwaysir, Ph.D., as Chief Executive Officer
Publications

Publications

Blood | April 27, 2023
In vivo HSC prime editing rescues sickle cell disease in a mouse model
JCI Insight | August 25, 2022
In vivo base editing by a single intravenous vector injection for treatment of hemoglobinopathies
Blood Advances | July 29, 2022
In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4
Blood Advances | February 23, 2021
In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice
Molecular Therapy | September 5, 2020
In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures sickle cell disease in a mouse model
JCI Insight | August 20, 2020
Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements
In the News

In the news

Evaluate Vantage | May 9, 2023
Gene editing: overhyped or unstoppable tide?
The Long Run with Luke Timmerman | April 24, 2023
Gene Editing Therapies Delivered In Vivo: Ensoma’s Emile Nuwaysir on The Long Run
BioPharma Dive | January 6, 2023
Ensoma buys a startup to advance ‘in vivo’ cell therapy work
BioCentury | January 6, 2023
In vivo cell therapy technology advances with Ensoma’s Twelve Bio acquisition
Nature Biotechnology | November 3, 2022
Nature Biotechnology’s academic spinouts 2021
BioPharma Dive | October 18, 2022
‘In vivo’ cell therapy: expanding beyond CAR-T

Like what you see?
Join our team.

See our current opportunities